Valuation: SANA AB

Market Cap 182.75Cr 19Cr 16Cr 15Cr 14Cr 26Cr 1.81TCr 27Cr 71Cr 883.53Cr 70Cr 69Cr 3.07TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 182.75Cr 19Cr 16Cr 15Cr 14Cr 26Cr 1.81TCr 27Cr 71Cr 883.53Cr 70Cr 69Cr 3.07TCr EV / Sales 2026 *
6.84x
EV / Sales 2027 * 4.71x
Free-Float
81.6%
Yield 2026 *
-
Yield 2027 * -
1 day-0.91%
1 week-0.90%
Current month+0.31%
1 month+1.47%
3 months-7.91%
6 months-47.50%
Current year-37.97%
1 week 12.81
Extreme 12.81
13.5
1 month 12.54
Extreme 12.54
13.83
Current year 12.25
Extreme 12.25
28.3
1 year 8.03
Extreme 8.03
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 01/03/2025
Chief Executive Officer 66 30/04/2022
Chief Tech/Sci/R&D Officer 68 01/01/2014
Director TitleAgeSince
Chairman 71 30/04/2022
Director/Board Member 68 01/01/2015
Director/Board Member 46 19/01/2018
Date Insider Type Main position Quantity % Market Cap.
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-0.68%-0.90%+40.34%+48.92% 19Cr
+1.23%-3.08%+53.96%+87.98% 5.53TCr
+5.09%+6.24%+63.15%+66.42% 5.42TCr
+0.86%-0.03%+3.86%+425.07% 2.31TCr
-0.25%+0.24%-19.91%-14.25% 2.32TCr
+1.03%-0.76%+40.14%-3.59% 2.03TCr
-0.37%+0.71%+31.36%-29.32% 1.79TCr
+0.87%-2.80%+37.96%+600.00% 1.58TCr
-2.54%-12.88%+168.62%+289.45% 1.5TCr
+0.77%-0.47%+22.14%+178.78% 1.38TCr
Average +0.58%-0.44%+44.16%+164.95% 2.39TCr
Weighted average by Cap. +1.50%+1.19%+45.43%+140.87%

Financials

2026 *2027 *
Net sales 27Cr 2.73Cr 2.4Cr 2.23Cr 2.05Cr 3.85Cr 264.65Cr 3.92Cr 10Cr 129.08Cr 10Cr 10Cr 447.83Cr 39Cr 3.97Cr 3.49Cr 3.24Cr 2.98Cr 5.59Cr 384.38Cr 5.69Cr 15Cr 187.49Cr 15Cr 15Cr 650.44Cr
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
43
Date Price Change Volume
23/26/23 SEK 13.15 -0.68% 1,64,092
22/26/22 SEK 13.24 +1.61% 3,10,266
21/26/21 SEK 13.03 +0.70% 2,53,062
20/26/20 SEK 12.94 -0.77% 2,02,188
17/26/17 SEK 13.04 -1.73% 2,43,260

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock